1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

• Source: Scrip

Iovance Biotherapeutics, Inc.’s tumor-infiltrating lymphocyte (TIL) Amtagvi (lifileucel) scored a win in February as the first cell therapy to win US Food and Drug Administration approval for a solid tumor indication. In the years ahead, more TIL, T-cell receptor (TCR) and chimeric antigen receptor T-cell (CAR-T) therapies will likely hit the market. But while it appears the age of cell therapy for solid tumors has finally arrived, each modality faces unique challenges not associated with CAR-T therapies approved for blood cancers.

Next-generation cell therapies, including Amtagvi, were the topic of a 2 June educational session at the recent American Society of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

More from Bio-Europe

Norway’s Nykode Eyes NASDAQ As Pipeline Advances

 
• By Kevin Grogan

CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.

Novartis Casts Nets Globally To Snap Up Best Assets

 
• By Kevin Grogan

The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.